poseltinib poseltinib poseltinib (hm71224, ly3337641) is an experimental bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. it was developed by hanmi pharmaceutical and licensed to eli lilly. poseltinibclinical dataother nameshm-7122; ly 3337641identifiers iupac name n-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furopyrimidin-4-yl)oxy)phenyl)acrylamide cas number1353552-97-2pubchem cid56644522uniid01e4b1u35chemical and physical dataformulac26h26n6o3molar mass470.533 g·mol−13d model (jsmol)interactive image smiles c=cc(=o)nc1cccc(oc2nc(nc3ccc(n4ccn(c)cc4)cc3)nc3ccoc23)c1 inchi inchi=1s/c26h26n6o3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17h,1,12-15h2,2h3,(h,27,33)(h,28,29,30)key:lzmjnvrjmfmyqs-uhfffaoysa-n phase ii clinical trials began in august 2016 in patients with rheumatoid arthritis. additional phase ii trials are planned for treatment of lupus, lupus nephritis, sjögren's syndrome, and other immunological conditions.